Innate Pharma S.A. (IPHA)

Innate Pharma Income Statement

Financials in millions EUR. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019	2018	2017
Revenue	61.64	57.67	24.7	69.77	85.45	93.95	44.03
Revenue Growth (YoY)	6.88%	133.47%	-64.60%	-18.35%	-9.05%	113.37%	-
Gross Profit	61.64	57.67	24.7	69.77	85.45	93.95	44.03
Selling, General & Admin	18.29	22.44	25.52	18.99	20.98	18.14	17.02
Research & Development	56.02	51.66	47	49.71	62.9	69.56	67
Other Operating Expenses	0	41	0	0	0	1.11	0
Operating Expenses	74.31	115.1	72.53	68.69	83.87	88.81	84.02
Operating Income	-12.67	-57.43	-47.83	1.08	1.58	5.15	-39.98
Interest Expense / Income	1.84	5.32	4	6.76	4.98	8.43	10.54
Other Expense / Income	-6.93	-4.64	0.99	58.3	17.36	-6	-2.5
Pretax Income	-7.57	-58.1	-52.81	-63.98	-20.76	2.72	-48.02
Income Tax	0	0	0	0	0	-0.33	0.37
Net Income	-7.57	-58.1	-52.81	-63.98	-20.76	3.05	-48.39
Shares Outstanding (Basic)	81	80	79	79	75	59	54
Shares Outstanding (Diluted)	-	-	-	-	-	59	54
Shares Change	0.78%	1.10%	0.57%	5.18%	27.11%	8.14%	-
EPS (Basic)	-0.09	-0.73	-0.66	-0.81	-0.31	0.05	-0.89
EPS (Diluted)	-0.09	-0.73	-0.66	-0.81	-0.31	0.05	-0.89
Free Cash Flow	-32.76	-19.69	-59.38	-52.67	33.65	-33.4	-50.97
Free Cash Flow Per Share	-0.41	-0.25	-0.75	-0.67	0.45	-0.57	-0.94
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-20.55%	-99.57%	-193.60%	1.55%	1.84%	5.48%	-90.80%
Profit Margin	-12.28%	-100.74%	-213.78%	-91.70%	-24.29%	3.25%	-109.88%
Free Cash Flow Margin	-53.14%	-34.14%	-240.37%	-75.48%	39.38%	-35.55%	-115.76%
Effective Tax Rate	-	-	-	-	-	-12.26%	-
EBITDA	-0.64	-7.38	-44.22	-0.42	0.75	18.55	-33.09
EBITDA Margin	-1.04%	-12.79%	-178.99%	-0.61%	0.87%	19.74%	-75.15%
Depreciation & Amortization	5.09	45.41	4.6	56.8	16.53	7.4	4.39
EBIT	-5.74	-52.78	-48.81	-57.22	-15.78	11.15	-37.48
EBIT Margin	-9.30%	-91.52%	-197.60%	-82.01%	-18.47%	11.86%	-85.12%

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).